Viatris (VTRS) Net Cash Flow Growth (3y) (2022 - 2026)
Powered by 
Analysis
Viatris (VTRS) Net Cash Flow Growth (3y) (2022 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 42.84 Bn | 39.19 Bn | 2.15 Bn | -28.90% |
| 2 | Viatris | 19.13 Bn | 18.24 Bn | 1.46 Bn | -106.21% |
| 3 | Dr Reddys Laboratories | 9.91 Bn | 9.74 Bn | 396.53 Mn | -63.55% |
| 4 | Amneal Pharmaceuticals | 5.51 Bn | 5.38 Bn | 334.51 Mn | -21.66% |
| 5 | Bausch Health Companies | 2.30 Bn | 464.50 Mn | 2.10 Bn | 111.26% |
| 6 | Alvotech | 1.50 Bn | 1.36 Bn | 2.56 Mn | - |
| 7 | Ani Pharmaceuticals | 1.49 Bn | 1.13 Bn | 165.89 Mn | -19.52% |
| 8 | Amphastar Pharmaceuticals | 1.00 Bn | 714.13 Mn | 93.47 Mn | 59.55% |
| 9 | Fennec Pharmaceuticals | 402.10 Mn | 360.85 Mn | 17.15 Mn | - |
| 10 | RedHill Biopharma | 178.35 Mn | 178.35 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -106.21% |
| Mar 31, 2026 | 37.74% |
| Dec 31, 2025 | -14.86% |
| Sep 30, 2025 | 349.65% |
| Jun 30, 2025 | -48.84% |
| Mar 31, 2025 | -62.13% |
| Dec 31, 2024 | -190.33% |
| Sep 30, 2024 | 118.49% |
| Jun 30, 2024 | 13.34% |
| Mar 31, 2024 | 63.37% |
| Dec 31, 2023 | -59.14% |
| Mar 31, 2023 | -101.97% |
| Dec 31, 2022 | 76.06% |